Comparative evaluation of clinical and inflammatory factors in response to the pharmacological managements in metabolic syndrome

Our study focused to assess the effect of various potential treatments on components of metabolic syndrome (MetS). This is a prospective, open-label, parallel group and randomized control trial of 90-day duration in which patients (n = 159) were randomly assigned in four groups to receive “diet and lifestyle modification” (n = 40), “metformin 500 mg twice daily” (n = 39), “pioglitazone 15 mg once daily” (n = 39), and “rosuvastatin 10 mg once daily” (n = 41). Clinical, biochemical, and inflammatory markers of each participant were evaluated. Fasting plasma glucose (FPG) level was lower in all except rosuvastatin group while HDL-cholesterol level increased in rosuvastatin group only (p < 0.05). Serum triglyceride was significantly and comparably decreased in both pioglitazone and rosuvastatin group (p < 0.05). Significant decrease in hsCRP and increase in serum adiponectin (p < 0.05) were reported in all the groups from baseline. The study can add a step forward in devising standard pharmacotherapeutic regimen beyond the current treatment modalities.